4.5 Article

The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results

Journal

EUROPEAN JOURNAL OF HUMAN GENETICS
Volume 26, Issue 7, Pages 984-995

Publisher

SPRINGERNATURE
DOI: 10.1038/s41431-018-0144-0

Keywords

-

Funding

  1. Canadian Institutes of Health Research (CIHR)
  2. University of Toronto McLaughlin Centre
  3. NCI [P30 CA008748]
  4. NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Guidelines recommend patients be informed of their incidental results (IR) when undergoing genomic sequencing (GS), yet there are limited tools to support patients' decisions about learning IR. The aim of this study is to develop and test the usability of a decision aid (DA) to guide patients' selection of IR, and to describe patients' preferences for learning IR following use of the DA. We developed and evaluated a DA using an iterative, mixed-methods process consisting of (1) prototype development, (2) feasibility testing, (3) cognitive interviews, (4) design and programming, and (5) usability testing. We created an interactive online DA called the Genomics ADvISER, a genomics decision AiD about Incidental SEquencing Results. The Genomics ADvISER begins with an educational whiteboard video, and then engages users in a values clarification exercise, knowledge quiz and final choice step, based on a 'binning' framework. Participants found the DA acceptable and intuitive to use. They were enthusiastic towards GS and IR; all selected multiple categories of IR. The Genomics ADvISER is a new patient-centered tool to support the clinical delivery of incidental GS results. The Genomics ADvISER fills critical care gaps, given the health care system's limited genomics expertise and capacity to convey the large volume of IR and their myriad of implications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Locus-of-care disparities in end-of-life care intensity among adolescents and young adults with cancer: A population-based study using the IMPACT cohort

Hallie Coltin, Adam Rapoport, Nancy N. Baxter, Chenthila Nagamuthu, Paul C. Nathan, Jason D. Pole, Franco Momoli, Sumit Gupta

Summary: Adolescents and young adults with cancer may receive high-intensity end-of-life care, with pediatric care and rural residence associated with higher odds of ICU death.

CANCER (2022)

Article Oncology

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

Nancy N. Baxter, Erin B. Kennedy, Emily Bergsland, Jordan Berlin, Thomas J. George, Sharlene Gill, Philip J. Gold, Alex Hantel, Lee Jones, Christopher Lieu, Najjia Mahmoud, Arden M. Morris, Erika Ruiz-Garcia, Y. Nancy You, Jeffrey A. Meyerhardt

Summary: The study aims to develop recommendations for adjuvant therapy for patients with resected stage II colon cancer.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Article Oncology

Obstetrical and Perinatal Outcomes in Female Survivors of Childhood and Adolescent Cancer: A Population-Based Cohort Study

Alina Zgardau, Joel G. Ray, Nancy N. Baxter, Chenthila Nagamuthu, Alison L. Park, Sumit Gupta, Paul C. Nathan

Summary: Female survivors of pediatric cancer have a lower likelihood of achieving pregnancy and, once pregnant, are at higher risk for preterm birth and maternal complications.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2022)

Editorial Material Oncology

Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities

Kenneth Offit, Catherine M. Sharkey, Dina Green, Xiaohan Wu, Magan Trottier, Jada G. Hamilton, Michael F. Walsh, Sita Dandiker, Sami Belhadj, Steven M. Lipkin, Thelma Alessandra Sugranes, Michele Caggana, Zsofia K. Stadler

Summary: Cancer predictive or diagnostic assays, known as Laboratory-Developed Tests (LDTs), lack proper regulatory oversight in the US. They enter the market without review, potentially jeopardizing patient safety. The proposed Verifying Accurate Leading-edge IVCT Development Act aims to harmonize regulations and address concerns over the quality, utility, and safety of LDTs for cancer genomics.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Oncology

Increasing Skin Cancer Prevention in Young Adults: the Cumulative Impact of Personalized UV Photography and MC1R Genetic Testing

Yelena P. Wu, Jada G. Hamilton, Kimberly A. Kaphingst, Jakob D. Jensen, Wendy Kohlmann, Bridget G. Parsons, Helen M. Lillie, Xuechen Wang, Benjamin Haaland, Ali P. Wankier, Douglas Grossman, Jennifer L. Hay

Summary: The study examined the unique and combined impacts of personalized ultraviolet (UV) radiation photographs, genetic testing for skin cancer risk, and general skin cancer prevention education. The combined intervention of UV photo and genetic testing had the most consistent positive effects on skin cancer prevention behaviors. Intervention effects varied across seasons.

JOURNAL OF CANCER EDUCATION (2023)

Article Oncology

Treatment of Metastatic Colorectal Cancer: ASCO Guideline

Van K. Morris, Erin B. Kennedy, Nancy N. Baxter, Al B. Benson, Andrea Cercek, May Cho, Kristen K. Ciombor, Chiara Cremolini, Anjee Davis, Dustin A. Deming, Marwan G. Fakih, Sepideh Gholami, Theodore S. Hong, Ishmael Jaiyesimi, Kelsey Klute, Christopher Lieu, Hanna Sanoff, John H. Strickler, Sarah White, Jason A. Willis, Cathy Eng

Summary: The purpose of this study is to develop treatment recommendations for patients with metastatic colorectal cancer (mCRC). An Expert Panel convened by ASCO conducted a systematic review of relevant studies and developed recommendations for clinical practice. Based on the inclusion criteria, five systematic reviews and ten randomized controlled trials were included in the analysis. The recommendations include offering doublet chemotherapy or triplet therapy to previously untreated mCRC patients who are initially unresectable, based on studies of chemotherapy combined with anti-vascular endothelial growth factor antibodies. Pembrolizumab is recommended for first-line treatment of mCRC patients with microsatellite instability-high or deficient mismatch repair tumors. Chemotherapy and anti-epidermal growth factor receptor therapy are recommended for microsatellite stable or proficient mismatch repair left-sided treatment-naive RAS wild-type mCRC, while chemotherapy and anti-vascular endothelial growth factor therapy are recommended for microsatellite stable or proficient mismatch repair RAS wild-type right-sided mCRC. Encorafenib plus cetuximab is recommended for previously treated BRAF V600E-mutant mCRC patients who have progressed after one previous line of therapy. Other recommendations are provided for patients with colorectal peritoneal metastases, liver metastases, and candidates for potentially curative resection of liver metastases. Multidisciplinary team management and shared decision making are also recommended.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Article Genetics & Heredity

Summary of the experiences, knowledge, medical management, and family communication of monoallelic MUTYH carriers

Danielle B. McKenna, Pauleen Sanchez, Jacquelyn Powers, Jamie Brower, Louise Wang, Rebecca Mueller, Heather Symecko, Jada G. Hamilton, Temima Wildman, Susan M. Domchek, Fergus J. Couch, Judy E. Garber, Kenneth Offit, Mark E. Robson, Bryson W. Katona

Summary: Germline genetic testing for inherited cancer risk often includes MUTYH on multigene panels. This study explored the experiences and understanding of monoallelic MUTYH carriers, finding overall satisfaction with healthcare management and familial communication. However, there were varying levels of knowledge regarding cancer risks and screening recommendations for MUTYH carriers.

JOURNAL OF GENETIC COUNSELING (2023)

Article Health Care Sciences & Services

Development and early-stage evaluation of a patient portal to enhance familial communication about hereditary cancer susceptibility testing: A patient-driven approach

Samantha Pollard, Deirdre Weymann, Rosalie Loewen, Jennifer Nuk, Sophie Sun, Kasmintan A. Schrader, Chiquita Hessels, Dean A. Regier

Summary: A patient portal was developed to improve familial communication for patients undergoing genetic testing for hereditary cancer syndromes. The portal includes educational information, a FAQ page, guidance for familial communication, and lay summaries of genetic test findings. Feedback from healthcare providers and patients was used to refine the portal.

HEALTH EXPECTATIONS (2023)

Article Psychology, Clinical

Associations between social COVID-19 exposure and psychological functioning

Malwina Lewicka, Jada G. Hamilton, Erika A. Waters, Heather Orom, Elizabeth Schofield, Marc T. Kiviniemi, Peter A. Kanetsky, Jennifer L. Hay

Summary: The negative impact of the COVID-19 pandemic on mental health is well-known, but little is known about how the involvement of someone with COVID-19 in one's social circle affects psychological functioning. This study found that social COVID-19 exposure was associated with increased anxiety, stress, and concerns about family members getting sick and engaging in substance abuse. These psychological effects were stronger in women, younger individuals, and those with lower income, suggesting that these groups are at a higher risk and should be prioritized in mental health recovery efforts.

JOURNAL OF BEHAVIORAL MEDICINE (2023)

Article Genetics & Heredity

Great expectations: patients' preferences for clinically significant results from genomic sequencing

Salma Shickh, Agnes H. Sebastian, Marc Clausen, Chloe Mighton, Christine F. Elser, Andrea Eisen, Larissa Waldman, Seema Panchal, Thomas Ward, June E. Carroll, Emily Glogowski, Kasmintan Schrader, Jordan A. Lerner-Ellis, Raymond Kim, Kevin E. Thorpe, Yvonne Bombard

Summary: This study aimed to understand patient preferences and factors influencing preferences for secondary findings from genomic sequencing. The majority of adult cancer patients in the trial expressed interest in receiving various types of secondary findings, even those without immediate medical actionability. Older participants were more interested in early-onset neurological diseases, and those with lower decisional conflict were more likely to select all categories. The results emphasize the importance of incorporating patient preferences into guidelines on secondary findings.

HUMAN GENETICS (2023)

Article Genetics & Heredity

Measuring high-risk parents' opinions about direct-to-consumer genetic testing for adult-onset inherited cancer syndromes in their adolescent and young adult children

Emily Hasser, Beth N. Peshkin, Jada G. Hamilton, Jamie Brower, Hannah Ovadia, Lainie Friedman Ross, Rosalba Sacca, Beth Tarini, Susan M. Domchek, Sarah Vittone, Marcelo Sleiman Jr, Claudine Isaacs, Sarah Knerr, Benjamin S. Wilfond, Kenneth P. Tercyak

Summary: Neither direct-to-consumer (DTC) genetic testing nor predictive genetic testing is recommended for minor children due to ethical concerns and low clinical utility. However, parents with disease-causing genetic variants may be interested in testing their children for inherited conditions. A study examined high-risk parents' opinions about pediatric DTC genetic testing and found that a majority held favorable opinions. The study also validated the use of the Pediatric Testing Attitudes Scale (P-TAS) in assessing parental opinions and identified factors that influenced these opinions.

JOURNAL OF GENETIC COUNSELING (2023)

Review Genetics & Heredity

A model for the return and referral of all clinically significant secondary findings of genomic sequencing

Rita Kodida, Emma Reble, Marc Clausen, Salma Shickh, Chloe Mighton, Jordan Sam, Nicole Forster, Seema Panchal, Melyssa Aronson, Kara Semotiuk, Tracy Graham, Yael Silberman, Susan Randall Armel, Jeanna M. McCuaig, Iris Cohn, Chantal F. Morel, Christine Elser, Andrea Eisen, June C. Carroll, Emily Glogowski, Kasmintan A. Schrader, Vanessa Di Gioacchino, Jordan Lerner-Ellis, Raymond H. Kim, Yvonne Bombard, Incidental Genom Study Team

Summary: Secondary findings identified through genomic sequencing can provide various health benefits to patients, but resource and capacity constraints pose challenges to their clinical management. Clinical workflows are needed to optimize the benefits of these findings.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration

Erica S. S. Tsang, Veronika Csizmok, Laura M. M. Williamson, Erin Pleasance, James T. T. Topham, Joanna M. M. Karasinska, Emma Titmuss, Intan Schrader, Stephen Yip, Basile Tessier-Cloutier, Karen Mungall, Tony Ng, Sophie Sun, Howard J. J. Lim, Jonathan M. M. Loree, Janessa Laskin, Marco A. A. Marra, Steven J. M. Jones, David F. F. Schaeffer, Daniel J. J. Renouf

Summary: Emerging evidence suggests a predictive role of homologous recombination deficiency (HRD) in gastrointestinal and thoracic malignancies. In this study, whole genome and transcriptomic data were reviewed to evaluate HRD scores and single base substitution 3 (SBS3) in advanced GI and thoracic cancers. The association between HRD and time to progression on platinum (TTPp) was examined, and it was found that SBS3 was more strongly associated with TTPp in GI malignancies. Tumors with gBRCA1/2 mutations and a somatic second alteration showed high SBS3 and HRD scores, indicating potential therapeutic targets.

NPJ PRECISION ONCOLOGY (2023)

Review Gastroenterology & Hepatology

Randomised controlled trials of non-pharmacological interventions to improve patient-reported outcomes of colonoscopy: a scoping review

Colin Sue-Chue-Lam, Matthew Castelo, Amina Benmessaoud, Teruko Kishibe, Diego Llovet, Christine Brezden-Masley, Amy Y. X. Yu, Jill Tinmouth, Nancy N. Baxter

Summary: A scoping review found limited research on non-pharmacological interventions to improve patient-reported outcomes of colonoscopy. There was significant variation in the characteristics and results of the included studies across different countries. Future research should focus on underinvestigated interventions and develop consensus-based guidelines for study design.

BMJ OPEN GASTROENTEROLOGY (2023)

Article Oncology

The Association of Oxaliplatin-Containing Adjuvant Chemotherapy Duration with Overall and Cancer-Specific Mortality in Individuals with Stage III Colon Cancer: A Population-Based Retrospective Cohort Study

Colin Sue-Chue-Lam, Christine Brezden-Masley, Rinku Sutradhar, Amy Y. X. Yu, Nancy N. Baxter

Summary: This study examined the association between the duration of oxaliplatin-containing adjuvant chemotherapy and mortality in stage III colon cancer. The results showed that compared to receiving a full course of treatment, patients who received only 50% of the course had slightly higher overall mortality and cancer-specific mortality, but the differences were not significant.

CURRENT ONCOLOGY (2023)

No Data Available